50% off Premium Yearly
Ishares Nasdaq BiotechnologyIBBTOP PICKMay 11, 2017Stock price when the opinion was issued
As of Jun 18, 2026. Market Open.
Healthcare sector outlook The sector has had a great bounce since March lows. A good way to play the COVID vaccine race. IBB is the best-known biotech ETF, but he does the XBI, because it's equal-weighted. XBI has had a great bounce. It's a great sector with reasonable valuations. The race for a COVID vaccine is a tailwind, of course. Biotech is a slow-growth area, which benefit from interest rates staying very low for the long term.
All biotech shares are pretty volatile, and there have been some pretty big moves in the last couple of months. He expects this to run up and hit the high of $380, and then run past that. This is a generational change. Good space to be in long-term. 10 years and you should be very happy.